Glucocorticoid Receptor Agonist Series for Versatile Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases such as atopic dermatitis, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and lupus nephritis lack effective new compounds beyond corticosteroids, calcineurin inhibitors, and biologics like dupilumab.
Innovation Solution
Development of novel glucocorticoid receptor agonists and their prodrugs, which are administered to patients to treat these diseases, including formulations for oral, topical, or subcutaneous delivery, and potential antibody drug conjugates for targeted tissue delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new glucocorticoid receptor agonist compounds are developed, then treatment effectiveness for autoimmune and inflammatory diseases is improved, but drug development complexity and time are increased
Solution Approach 1:
The patent segments the glucocorticoid receptor agonist development into distinct chemical series (Formulas I, Ia, Ib, Ic, II, III) with systematic variations of substituents (R, R1, R2, R3, X groups). This segmentation allows researchers to methodically explore structure-activity relationships by modifying specific positions while keeping others constant, thereby managing development complexity while improving treatment effectiveness through optimized molecular structures.
Solution Approach 2:
The patent applies parameter changes by systematically varying chemical parameters (substituent types, positions, and combinations) of the glucocorticoid receptor agonist molecules. By changing parameters such as R (H or specific groups), R1 (various functional groups), R2 (H, halogen, alkyl, alkoxy, or alkenyl), and X (different linkers), the patent optimizes drug-receptor interaction to enhance treatment effectiveness while maintaining a structured approach to complexity management.
2Adaptability or versatility
If multiple formulation options (oral, topical, subcutaneous) are provided, then treatment versatility is improved, but manufacturing complexity is increased
Solution Approach 1:
The patent creates a universal glucocorticoid receptor agonist platform (compounds of Formulas I, Ia, Ib, Ic, II, III) that can be adapted for multiple routes of administration (oral, topical, subcutaneous, parenteral). This multi-functional approach allows the same core molecular structures to serve different therapeutic needs and delivery methods, improving treatment versatility while using standardized manufacturing processes for the core compounds that can then be formulated differently.
Solution Approach 2:
The patent uses prodrugs as intermediary forms that can be converted to active glucocorticoid receptor agonists in vivo. These prodrug intermediates (compounds where R is a specific protecting group) allow the drug to be administered in various formulations while maintaining stability during manufacturing and storage, then converting to the active form at the site of action, thereby simplifying manufacturing complexity while improving treatment versatility.
3Measurement precision
If antibody drug conjugates are developed for targeted delivery, then treatment precision is improved, but device complexity is increased
Solution Approach 1:
The patent employs antibody drug conjugates as intermediary delivery systems that combine the glucocorticoid receptor agonist (compounds of Formulas I, Ia, Ib, Ic, II, III) with targeting antibodies. The antibody component acts as an intermediary that directs the drug to specific tissues or cells expressing the target antigen, improving treatment precision by ensuring the active compound reaches the intended site while the conjugate structure manages the complexity of targeted delivery.
Data Source
AI summary
The present invention provides a compound of Formula I:wherein R is H orR1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3,R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl;R3 is NH2, or CH2NH2; andX is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.